Jennitte Stevens is an Executive Director of Drug Substance Technology in Process Development at Amgen. She leads the pre-pivotal Drug Substance Technologies organization, which is responsible for commercial cell line development and FIH drug substance process development for Amgen’s innovative multimodality pipeline, including Biologics, Synthetics, siRNA and T cell therapies. She joined Amgen in 2005 in the Protein Sciences Department in Discovery Research, with a focus on advancing protein expression technologies, protein engineering and molecule assessment of biologic therapeutics, and later joined Process Development, leading Amgen’s Cell Line Development and Genetic Characterization group. Through roles of increasing responsibility at Amgen, Jennitte has enabled the advancement of Amgen’s innovative early stage biologic portfolio and enabled the transition of many programs from Research in to Process Development. She has been instrumental in advancing Amgen’s expression platforms, biologics informatics tools, and implementation of cutting-edge technologies to improve efficiency and shorten timelines. Prior to Amgen, Jennitte worked at AmCyte (Santa Monica, CA) focusing on stem cell culture and differentiation to enable pancreatic islet cell therapies. Jennitte earned her Ph.D. at UCLA in the Molecular Biology Institute (MBI), studying mechanisms of transcriptional activation in mammalian cells.